Acceleron Pharma (XLRN) Misses Q1 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q1 EPS by 12c

Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results

May 8, 2017 7:00 AM EDT

- Luspatercept MEDALIST and BELIEVE Phase 3 trials expected to complete enrollment in Q2 2017 -

- Presented results from ongoing Phase 2 trial with luspatercept at the 14th International Symposium on MDS -

- Announced plans to initiate luspatercept Phase 3 trial in first-line, lower-risk MDS in early 2018 -

- Announced plans to initiate ACE-083 Phase 2 study in Charcot-Marie-Tooth disease -

- Maintained strong balance sheet with $213.2 million in cash, cash equivalents and investments to fund projected operating requirements into the second... More